News

NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.

Esen K. Akpek, MD, speaks with the Eye Care Network in recognition of Dry Eye Awareness Month.

A new pilot trial tests ZOC2017217 lanosterol-derived cataract eye drops, aiming to slow lens clouding and guide Phase 3 development amid mixed human evidence.

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

Antineoplastics were the most frequently implicated drug class in review

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, stated that preparing optometric students for the possibility of burnout may help reduce its prevalence.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her AOA Optometry's Meeting 2026 session.

Alcon's TikTok, YouTube, and Instagram campaign uses creator-led patient stories to reintroduce LASIK to younger consumers and prompt conversations with surgeons.

Healome’s proprietary eye drop-matrix behaves like a liquid when it is dropped on the eye, and then restructures on the ocular surface to form a clear, lubricating, protective matrix that can deliver a broad range of drugs.

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop, for the treatment of presbyopia in adults.

As of July 13, 2026, a meeting date has not been set.

Screen time's derailing of the circadian rhythm could contribute to behavioral difficulties in pediatric patients.

The new patient, secured by Provectus and VisiRose, supports a light-independent rose bengal eye drop that fights MRSA and other drug-resistant keratitis, erases biofilms, and enables self-administered treatment.

The FDA issued a nationwide recall of a steroid eye drop.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her session on the hormonal and aesthetic considerations ODs should make when treating these patients.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

LENZ Therapeutics and Arrotex Pharmaceuticals announce exclusive license and commercialization agreement for Vizz in Australia and New Zealand.

The meeting featured advances in contact lens technology, evolving approaches to keratoconus management, and new insights into dry eye disease treatment.

Ping Moore, OD, outlines modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Jade Coats, OD, FAAO, details what has changed in dry eye treatment in the last decade, and how to optimize the ocular surface through the power of comanagement.

Optometry's meetings thus far reveal a field in motion: earlier glaucoma intervention, an expanding dry eye pipeline, breakthrough myopia data, and sharper contact lens and retinal evaluation.

Justin Schweitzer, OD, FAAO, details how to distinguish secondary glaucomas from primary glaucomas in a recent presentation.

Jessica Steen, OD, FAAO, DipABO, weighs in on what the optometric community should know concerning what side effects their patients may experience.

A summary of major FDA approvals and CRLs in eye care from the first half of 2026.

Host Hamza Shah, OD, MS, FAAO, is joined by Brianna Rhue, OD, FAAO, to discuss eye care terminology, inspired by Zhang et al's paper, "Myopia Progression Management: Current Trends and Future Directions."

An overview of the diagnosis and evidence-based management of one of the most common causes of visual acuity reduction following intraocular surgery.